journal
MENU ▼
Read by QxMD icon Read
search

New England Journal of Medicine

journal
https://read.qxmd.com/read/31091368/has-the-genome-granted-our-wish-yet
#1
David J Hunter, Jeffrey M Drazen
No abstract text is available yet for this article.
May 15, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31091367/the-hospital-readmissions-reduction-program-time-for-a-reboot
#2
Rishi K Wadhera, Robert W Yeh, Karen E Joynt Maddox
No abstract text is available yet for this article.
May 15, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31075187/placebo-controlled-trial-of-an-oral-btk-inhibitor-in-multiple-sclerosis
#3
Xavier Montalban, Douglas L Arnold, Martin S Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Jonathan Willmer, Emily C Martin, Fernando Dangond, Sana Syed, Jerry S Wolinsky
BACKGROUND: Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo. METHODS: In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label dimethyl fumarate (DMF) as a reference...
May 10, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31067365/collateral-benefits-of-preventive-chemotherapy-expanding-the-war-on-neglected-tropical-diseases
#4
Peter J Hotez, Alan Fenwick, David H Molyneux
No abstract text is available yet for this article.
May 8, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31067364/sitting-in-limbo-obamacare-under-divided-government
#5
Jonathan Oberlander
No abstract text is available yet for this article.
May 8, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31059641/targeting-huntingtin-expression-in-patients-with-huntington-s-disease
#6
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Roger A Barker, Nick F Blair, David Craufurd, Josef Priller, Hugh Rickards, Anne Rosser, Holly B Kordasiewicz, Christian Czech, Eric E Swayze, Daniel A Norris, Tiffany Baumann, Irene Gerlach, Scott A Schobel, Erika Paz, Anne V Smith, C Frank Bennett, Roger M Lane
BACKGROUND: Huntington's disease is an autosomal-dominant neurodegenerative disease caused by CAG trinucleotide repeat expansion in HTT , resulting in a mutant huntingtin protein. IONIS-HTTRx (hereafter, HTTRx ) is an antisense oligonucleotide designed to inhibit HTT messenger RNA and thereby reduce concentrations of mutant huntingtin. METHODS: We conducted a randomized, double-blind, multiple-ascending-dose, phase 1-2a trial involving adults with early Huntington's disease...
May 6, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31059640/oligonucleotide-treatment-for-huntington-s-disease
#7
EDITORIAL
Kenneth H Fischbeck, Nancy S Wexler
No abstract text is available yet for this article.
May 6, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31050279/eculizumab-in-aquaporin-4-positive-neuromyelitis-optica-spectrum-disorder
#8
Sean J Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Kenji P Fujita, Róisín Armstrong, Dean M Wingerchuk
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nervous system. In a previous small, open-label study involving patients with AQP4-IgG-positive disease, eculizumab, a terminal complement inhibitor, was shown to reduce the frequency of relapse...
May 3, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31042823/pharmaceutical-protections-in-u-s-trade-deals-what-do-americans-get-in-return
#9
Thomas Bollyky, Aaron S Kesselheim
No abstract text is available yet for this article.
May 1, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31042822/aids-in-america-back-in-the-headlines-at-long-last
#10
Wafaa M El-Sadr, Kenneth H Mayer, Miriam Rabkin, Sally L Hodder
No abstract text is available yet for this article.
May 1, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31042821/lessons-from-scott-county-progress-or-paralysis-on-harm-reduction
#11
Sanjay Kishore, Margaret Hayden, Josiah Rich
No abstract text is available yet for this article.
May 1, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31034184/liraglutide-in-children-and-adolescents-with-type-2-diabetes
#12
William V Tamborlane, Margarita Barrientos-Pérez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett
BACKGROUND: Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown. METHODS: Patients who were 10 to less than 17 years of age were randomly assigned, in a 1:1 ratio, to receive subcutaneous liraglutide (up to 1...
April 28, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31018066/no-shortcuts-to-safer-opioid-prescribing
#13
Deborah Dowell, Tamara Haegerich, Roger Chou
No abstract text is available yet for this article.
April 24, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31018065/a-temporizing-solution-to-artemisinin-resistance
#14
Jigang Wang, Chengchao Xu, Fu Long Liao, Tingliang Jiang, Sanjeev Krishna, Youyou Tu
No abstract text is available yet for this article.
April 24, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31034183/tezepelumab-in-adults-with-uncontrolled-asthma
#15
(no author information available yet)
No abstract text is available yet for this article.
April 18, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30995368/measles-in-2019-going-backward
#16
Catharine I Paules, Hilary D Marston, Anthony S Fauci
No abstract text is available yet for this article.
April 17, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30995367/responding-to-evolving-abortion-regulations-the-critical-role-of-primary-care
#17
Jessica Beaman, Dean Schillinger
No abstract text is available yet for this article.
April 17, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30990261/clinical-credence-sglt2-inhibitors-diabetes-and-chronic-kidney-disease
#18
EDITORIAL
Julie R Ingelfinger, Clifford J Rosen
No abstract text is available yet for this article.
April 14, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30990260/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy
#19
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, Christopher P Cannon, George Capuano, Pei-Ling Chu, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Gary Meininger, Barry M Brenner, Kenneth W Mahaffey
BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS: In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo...
April 14, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30969507/treatment-of-progressive-multifocal-leukoencephalopathy-with-pembrolizumab
#20
LETTER
Sebastian Rauer, Reinhard Marks, Horst Urbach, Klaus Warnatz, Avindra Nath, Steve Holland, Cornelius Weiller, Bodo Grimbacher
No abstract text is available yet for this article.
April 10, 2019: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"